|
BUYINS.NET: (ALNY) SqueezeTrigger Price is $17.104. There is $100,373,805.00 That Short Sellers Still Need To Cover
Nov 02, 2009 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.squeezetrigger.com is monitoring ALNYLAM PHARMACEU (NYSE:ALNY) in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 5852700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $17.104. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
From January 2005 to October 2009, an aggregate amount of 62482005 shares of ALNY have been shorted for a total dollar value of $1,062,194,085.00. The ALNY SqueezeTrigger price of $17.104 is the volume weighted average price that all shorts are short in shares of ALNY. There is still approximately $100,373,805.00 of potential short covering in shares of ALNY.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .
ALNYLAM PHARMACEU (NYSE:ALNY) Alnylam Pharmaceuticals, Inc. (Alnylam), incorporated in May 2003, is a biopharmaceutical company that seeks to develop and commercialize new drugs that work through a discovered system in cells known as RNA interference (RNAi). The Company is focused on discovering, developing and commercializing RNAi therapeutics by establishing alliances with pharmaceutical companies. Alnylam has devoted its efforts to business planning, research and development, acquiring intellectual property rights, recruiting management and technical staff, and raising capital. The Company's initial drug development programs are focused on products that are called Direct RNAi therapeutics, because they will be administered directly to diseased parts of the body. The Company is also establishing capabilities for the development of products called Systemic RNAi therapeutics, because they will travel through the blood stream to reach diseased parts of the body.
The Company's most advanced product candidate is ALN-RSV01, a Direct RNAi therapeutic for the treatment of lung infections caused by respiratory syncytial virus (RSV). Alnylam initiated human clinical trials of ALN-RSV01 in December 2005. Its program to develop an RNAi therapeutic for pandemic flu is being conducted in collaboration with Novartis Institutes for Biomedical Research, Inc. (Novartis), an affiliate of Novartis Pharma AG. Alnylam also has discovery programs to develop Direct RNAi therapeutics for the treatment of the genetic respiratory disease known as cystic fibrosis and nervous system disorders, such as spinal cord injury, Parkinson's disease, Huntington's disease and neuropathic pain. The Company also has discovery programs in ocular diseases, such as age-related macular degeneration and several other diseases that are the subject of collaborations with Merck and Co., Inc.
Development Programs
In the Company's pre-clinical testing, ALN-RSV01 was shown to be an RSV-specific siRNA that is effective in both preventing and treating RSV infection in mice when administered intranasally, or through the nose. ALN-RSV01 also showed no significant toxicities in IND-enabling toxicology studies. Alnylam submitted an investigational new drug application (IND) for intranasal ALN-RSV01 to the United States Food and Drug Administration (FDA) in November 2005, and initiated Phase I clinical trials on this experimental drug in December 2005 in both the United States and Europe.
The focus of the pandemic flu program is to develop an RNAi therapeutic targeting gene sequences that are conserved across known flu viruses. In December 2005, Alnylam was awarded initial funding for its pandemic flu program from the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense. In connection with this program, in February 2006, the Company entered into a new collaboration with Novartis to develop RNAi therapeutics for pandemic flu.
Discovery Programs
The Company is conducting research activities to discover Direct RNAi therapeutics to treat various diseases of the respiratory system, the central nervous system (CNS), and the eye. The diseases for which Alnylam has discovery programs include: cystic fibrosis, which is an inherited respiratory disorder caused by mutations in the gene for a protein known as the cystic fibrosis transmembrane conductance regulator (CFTR); spinal cord injury (SCI) program, which is focused on a cellular system known as the Nogo pathway that appears to play a key role in blocking the regeneration of nerves in the spinal cord and brain after injury; Huntington's disease (HD), in which Alnylam is seeking to develop a novel drug-device product incorporating an RNAi therapeutic that will protect these cells by suppressing production of huntingtin; Parkinson's disease (PD), in which the Company's goal is to develop an RNAi therapeutic that will protect these cells by suppressing production of alpha-synuclein; and neuropathic pain, in which a protein called sodium channel NaV1.
The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly one billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
CONTACT: Thomas Ronk, CEO, SqueezeTrigger.com
Tel: +1 800 715 9999
e-mail: Tom@SqueezeTrigger.com
WWW: http://www.SqueezeTrigger.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
[ Back To it.tmcnet.com's Homepage ]
|